--- title: "RBC 表示，丹納赫在生物工藝恢復的推動下被視為重新加速增長" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/286592573.md" description: "RBC 資本市場預測，丹納赫（Danaher，股票代碼：DHR）在 2027 年可能實現 6% 的收入增長，這得益於生物處理需求的反彈和市場的改善。該公司指出，生物處理耗材和設備的需求強勁。丹納赫還在解決其貝克曼庫爾特（Beckman Coulter）業務中的不足，並預計其收購馬西莫（Masimo）將帶來增長。儘管股價下跌 1.1% 至 162.75 美元，RBC 仍恢復了對該公司的覆蓋，給予 “跑贏大盤” 的評級，並設定 200 美元的目標價" datetime: "2026-05-15T15:58:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286592573.md) - [en](https://longbridge.com/en/news/286592573.md) - [zh-HK](https://longbridge.com/zh-HK/news/286592573.md) --- # RBC 表示，丹納赫在生物工藝恢復的推動下被視為重新加速增長 11:58 AM EDT, 05/15/2026 (MT Newswires) -- Danaher ( DHR ) could see about 6% revenue growth in 2027, driven by a rebound in bioprocess demand trends and improving end markets, RBC Capital Markets said. RBC's channel checks indicate robust demand trends for bioprocess consumables and expanding equipment funnels, according to the note. This positions Danaher ( DHR ) to benefit from the sector recovery as bioprocessing represents more than 25% of the company's revenue, the investment firm said in a Thursday note. Danaher ( DHR ) is also working to close menu gaps in its Beckman Coulter business and sees continued improvement in its molecular diagnostics segment amid a recovering underlying diagnostics market. The company could see further growth upside from its Masimo (MASI) acquisition, which is expected to close in the second half of 2026, RBC added. RBC Capital Markets resumed coverage on Danaher ( DHR ), with an outperform rating and a $200 price target. Shares of Danaher ( DHR ) were down 1.1% in Friday afternoon trading. Price: 162.75, Change: -1.79, Percent Change: -1.09 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited. ### 相關股票 - [DHR.US](https://longbridge.com/zh-HK/quote/DHR.US.md) - [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md) - [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md) - [XHE.US](https://longbridge.com/zh-HK/quote/XHE.US.md) - [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md) - [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md) - [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md) - [IHI.US](https://longbridge.com/zh-HK/quote/IHI.US.md) - [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md) - [RY.US](https://longbridge.com/zh-HK/quote/RY.US.md) - [MASI.US](https://longbridge.com/zh-HK/quote/MASI.US.md) ## 相關資訊與研究 - [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md) - [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md) - [Resona Asset Management Co. Ltd. 減少了丹納赫公司 $DHR 的持倉](https://longbridge.com/zh-HK/news/286897088.md) - [西北互助財富管理公司收購了丹納赫公司 186,584 股股票 $DHR](https://longbridge.com/zh-HK/news/286744959.md) - [Jenscare 的 LuX-Valve Plus 在大瓣環三尖瓣患者中表現出強勁的一年期結果](https://longbridge.com/zh-HK/news/287144318.md)